The efficacy of voxelotor, 900 mg in patients with sickle cell anemia: a meta-analysis of the randomized controlled trials

Department of Medical Pharmacology, Faculty of Medicine, Inonu University, Malatya, Turkey. Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey.

International journal of clinical practice. 2020;:e13967
Sickle cell anemia (SCA) is an autosomal recessive disease caused by a mutation in the gene that codes the β-globin chain of hemoglobin. The abnormal hemoglobin (hemoglobin S) can polymerize when deoxygenated, changing the physical properties of the red cells (which deform to a sickle shape, hence the name) and damages cell membranes.(1) Sickle cell anemia can lead to a variety of signs and symptoms namely vaso-occlusive attacks (presenting as pain, tissue hypoxia, necrosis, and organ damage), acute chest syndrome, hemolytic crisis, and primary and secondary stroke.
Study details
Study Design : Systematic Review
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine